PFG Advisors’s Novo Nordisk NVO Stock Holding History

PFG Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,088	Closed	-$583K	–	711
2024 Q2	$583K	Sell	4,088 -5	-0.1%	-$663	0.04%	394
2024 Q1	$525K	Buy	4,093 +131	+3%	+$15.6K	0.04%	382
2023 Q4	$410K	Buy	+3,962	New	+$392K	0.03%	401

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFG Advisors's NVO Position: Q3 2024 in Review

PFG Advisors sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 4,088 shares — an estimated $583K sold.

PFG Advisors first reported a position in NVO in Q4 2023 and held it in 3 quarters. The position peaked at $583K in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

PFG Advisors reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
PFG Advisors sold 4,088 Novo Nordisk shares in Q3 2024, an estimated $583K.
PFG Advisors first reported a position in Novo Nordisk in Q4 2023 and held it in 3 quarters.
PFG Advisors's Novo Nordisk position peaked at $583K in Q2 2024.
1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on PFG Advisors's 13F filing for Q3 2024, filed 15 Oct 2024.